Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Karabo Serala und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Biology, University of Cape Town, Observatory, Cape Town, South Africa. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Gemcitabine, Deoxycytidine, Pyrvinium Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Centre for Genetic Engineering and Biotechnology, National Research Foundation of South Africa, University of Cape Town (UCT Vision 2030 Grand Challenges Programme).
Abstract (Originalsprache)
Pancreatic cancer is an intractable disease with the worst prognosis of all common cancers. The treatment regimens currently used for pancreatic cancer do not significantly impact patient survival, and therefore, effective treatment strategies are urgently needed. Drug repurposing, which identifies new indications for existing and approved drugs, has proven to be a desirable approach to anti‐cancer drug discovery. Indeed, the antihelminthic drug, pyrvinium pamoate, has shown promise as an anti‐pancreatic cancer drug. However, the only mechanism of action ascribed to this has been its ability to inhibit mitochondrial function. This study showed, using pancreatic cancer 2D cell cultures and 3D spheroids, that pyrvinium pamoate exhibited short‐ and long‐term cytotoxicity, inhibited epithelial‐to‐mesenchymal transition and cell invasion and migration. Mechanistically, pyrvinium pamoate induced DNA damage, inhibited stemness markers and the PI3K/AKT cell survival pathway, triggered an S‐phase cell cycle arrest and induced apoptotic and autophagic cell death. Importantly, pyrvinium pamoate acted synergistically with the first‐line drug, gemcitabine, in 2D and 3D pancreatic cancer cell culture models. This study provides evidence that pyrvinium pamoate is effective as a single agent and in combination with gemcitabine for the treatment of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Biology, University of Cape Town, Observatory, Cape Town, South Africa.
ORCID-Profile: Jinming Bai, Sharon Prince
Förderung
- International Centre for Genetic Engineering and Biotechnology
- National Research Foundation of South Africa
- University of Cape Town (UCT Vision 2030 Grand Challenges Programme)
- South African Medical Research Council
- University of Capetown
Zitieren
APA
Serala, K., Bai, J., & Prince, S. (2024). Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70222
Vancouver
Serala K, Bai J, Prince S. Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70222
BibTeX
@article{Serala2024,
author = {Serala, Karabo and Bai, Jinming and Prince, Sharon},
title = {Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70222}
}
EUVIMED